骨髓發育不良症候群市場：按給藥途徑、藥物類別分類 - 2023-2030 年全球預測

骨髓發育不良症候群的全球市場預計到 2023 年將達到 25.9057 億美元，年複合成長率為 10.05%，預計到 2030 年將以 50.7171 億美元的驚人速度成長。

FPNV定位矩陣

FPNV定位矩陣對於評估全球骨髓發育不良症候群市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.骨髓發育不良症候群的全球市場規模和預測是多少？

2.在預測期內，COVID-19 對全球骨髓發育不良症候群市場的阻礙因素與影響有哪些？

3.在預測期內，全球骨髓發育不良症候群市場需要投資哪些產品/細分市場/應用/領域？

4.你們在全球骨髓發育不良症候群市場的競爭策略是什麼？

5. 全球骨髓發育不良症候群市場的技術趨勢和法律規範是什麼？

6.全球骨髓發育不良症候群市場主要供應商的市佔率是多少？

7. 哪些型態和策略性措施被認為適合進入全球骨髓發育不良症候群市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 老年人口增加，此症候群的發生率增加
    • 改善醫療保健服務以及幹細胞移植和放射治療的進步
    • 更容易獲得和獲得新的治療方法
  • 抑制因素
    • 新療法的成本高昂
  • 機會
    • 開發強大的藥物管道
    • 報銷政策等政府支持舉措
  • 任務
    • 新治療方法的複雜性和異質性
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 骨髓發育不良症候群市場：依給藥途徑

• 口服
• 胃腸外的

第7章 按藥物類別分類的骨髓發育不良症候群市場

• 烷基化劑
• 細胞毒性抗生素
• 拓樸異構酶抑制劑

第8章 美洲骨髓發育不良症候群市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第9章 亞太骨髓骨髓發育不良症候群市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第10章 歐洲、中東和非洲骨髓發育不良症候群市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第11章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第12章上市公司名單

第13章附錄

• 討論指南
• 關於許可證和定價

The Global Myelodysplastic Syndrome Market is forecasted to grow significantly, with a projected USD 2,590.57 million in 2023 at a CAGR of 10.05% and expected to reach a staggering USD 5,071.71 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Myelodysplastic Syndrome Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Myelodysplastic Syndrome Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Route of Administration, market is studied across Oral and Parenteral. The Parenteral is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Alkylating Agents, Cytotoxic Antibiotics, and Topoisomerase Inhibitors. The Alkylating Agents is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Myelodysplastic Syndrome Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Myelodysplastic Syndrome Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Myelodysplastic Syndrome Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Myelodysplastic Syndrome Market?

4. What is the competitive strategic window for opportunities in the Global Myelodysplastic Syndrome Market?

5. What are the technology trends and regulatory frameworks in the Global Myelodysplastic Syndrome Market?

6. What is the market share of the leading vendors in the Global Myelodysplastic Syndrome Market?

7. What modes and strategic moves are considered suitable for entering the Global Myelodysplastic Syndrome Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Myelodysplastic Syndrome Market, by Route of Administration, 2022 vs 2030
• 4.3. Myelodysplastic Syndrome Market, by Drug Class, 2022 vs 2030
• 4.4. Myelodysplastic Syndrome Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising geriatric population and increasing incidence of the syndrome
    • 5.1.1.2. Improvements in healthcare services and advancements in stem cell transplantation and radiation therapy
    • 5.1.1.3. Easy of availability and access to novel treatments
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of novel therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of strong drug pipeline
    • 5.1.3.2. Supportive government initiatives such as reimbursement policies
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity and heterogeneity of novel treatment
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Myelodysplastic Syndrome Market, by Route of Administration

• 6.1. Introduction
• 6.2. Oral
• 6.3. Parenteral

7. Myelodysplastic Syndrome Market, by Drug Class

• 7.1. Introduction
• 7.2. Alkylating Agents
• 7.3. Cytotoxic Antibiotics
• 7.4. Topoisomerase Inhibitors

8. Americas Myelodysplastic Syndrome Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Myelodysplastic Syndrome Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Myelodysplastic Syndrome Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. MYELODYSPLASTIC SYNDROME MARKET RESEARCH PROCESS
• FIGURE 2. MYELODYSPLASTIC SYNDROME MARKET SIZE, 2022 VS 2030
• FIGURE 3. MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
• FIGURE 5. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 6. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. MYELODYSPLASTIC SYNDROME MARKET DYNAMICS
• FIGURE 8. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. MYELODYSPLASTIC SYNDROME MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. MYELODYSPLASTIC SYNDROME MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. MYELODYSPLASTIC SYNDROME MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 5. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CYTOTOXIC ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 12. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 14. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 15. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 16. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 17. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 18. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 19. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 20. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 21. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 22. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 23. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 25. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 28. AUSTRALIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 29. AUSTRALIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. CHINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. CHINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. INDIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. INDIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 34. INDONESIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 35. INDONESIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. JAPAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. JAPAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 38. MALAYSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. MALAYSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. PHILIPPINES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. PHILIPPINES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 42. SINGAPORE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. SINGAPORE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. SOUTH KOREA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. SOUTH KOREA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 46. TAIWAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. TAIWAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. THAILAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. THAILAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. VIETNAM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. VIETNAM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 52. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. DENMARK MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. DENMARK MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. EGYPT MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. EGYPT MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. FINLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. FINLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. ISRAEL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. ISRAEL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 67. ITALY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. ITALY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. NETHERLANDS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. NETHERLANDS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. NIGERIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. NIGERIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. NORWAY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. NORWAY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 75. POLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. POLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. QATAR MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. QATAR MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 79. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. SAUDI ARABIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. SAUDI ARABIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. SOUTH AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. SPAIN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. SPAIN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. SWEDEN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. SWEDEN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. SWITZERLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. SWITZERLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. TURKEY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. TURKEY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. UNITED ARAB EMIRATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. UNITED ARAB EMIRATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 95. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. MYELODYSPLASTIC SYNDROME MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 98. MYELODYSPLASTIC SYNDROME MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 99. MYELODYSPLASTIC SYNDROME MARKET LICENSE & PRICING